The trial record
PT-141 Research: The Bremelanotide Evidence, Study by Study
From the first animal pharmacology to the pivotal RCTs and the re-analyses that push back — appraised, not just listed.
Before the details
PT-141 research is unusually deep for a peptide most people meet informally. This page walks the record from the bottom up: the early animal and human pharmacology that established a central (brain-based) mechanism; the two pivotal trials that earned approval; the mechanistic brain-imaging study; the animal data that complicates the reward story; and the critical re-analyses arguing the effect is real but small. The aim is appraisal — for each finding, how good is the study, and what does it actually license us to claim? PT-141 acts on melanocortin receptors in the brain, which is the fact every downstream finding hangs on, so we start there [1]. Jargon is glossed on first use; the firm conclusions are the blinded, placebo-controlled ones, and we say so when a study falls short of that bar.
What is PT-141 peptide
PT-141 peptide is bremelanotide: a synthetic cyclic heptapeptide (a ring of seven amino acids) and a lactam-bridged analogue of alpha-MSH, the body's own melanocortin signal [1]. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a molecular weight of about 1025 Da; the cyclic ring gives it more stability than linear melanocortin peptides [1]. It is a structural relative of melanotan II but with the C-terminal amide replaced by a carboxylic acid, which shifts its receptor profile toward MC3R/MC4R activity over the pigmentation-dominant MC1R [1]. Functionally, that chemistry is the whole point: PT-141 is built to reach central melanocortin receptors and influence sexual motivation, not to act peripherally.
Mechanism: central, not vascular
The foundational pharmacology established a central mechanism. Systemic PT-141 produced penile erections in rats and nonhuman primates and increased c-Fos (a marker of neuronal activation) in the hypothalamus, and produced rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. It works by agonizing MC4R (and MC3R) in hypothalamic circuits such as the medial preoptic area, engaging dopaminergic signaling for appetitive sexual behavior [1]. Two pieces of evidence pin the "central, not peripheral" claim: human fMRI showing altered brain processing after dosing [5], and an in vitro study where bremelanotide (1 µM) failed to relax rabbit vaginal tissue while alpha-MSH relaxed it — direct evidence against a peripheral vascular mechanism [13]. This is why PT-141 is mechanistically unlike a PDE-5 inhibitor.
The pivotal trials
The approval evidence is the RECONNECT program: two identical, randomized, double-blind, placebo-controlled Phase 3 trials in 1267 premenopausal women with HSDD [3]. Both met coprimary endpoints — integrated FSFI-desire +0.35 and integrated desire-distress item −0.33, each P<.001 over 24 weeks — with nausea, flushing, and headache the leading adverse events [3]. A 52-week open-label extension (684 women) found sustained efficacy and no new safety signals, with nausea (40.4%), flushing (20.6%), and headache (12.0%) the most common drug-related events [4]. Appraisal note: the RCTs are high-tier evidence for the approved indication; the extension, being open-label, is durability evidence of a lower tier. Supporting reviews position bremelanotide as a centrally acting agent with good evidence for HSDD while emphasizing how few approved options exist [11][12].
PT-141 for men and PT-141 for women
The evidence is asymmetric by sex, and a fair review says so. For women, the record is robust: pivotal RCTs, an extension, mechanistic fMRI, and preclinical work showing PT-141 selectively increased appetitive (solicitational) sexual behavior in female rats without affecting reflexive lordosis or motor activity — early evidence that central melanocortin systems regulate female desire [2][3][5]. PT-141 for men rests on a thinner, older base: the early pharmacology showing erectile activity [1] and disputed clinical work, including a 2008 erectile-dysfunction study that drew a 2023 Expression of Concern. Use in men is off-label and not supported by an approval-grade trial. So "PT-141 for women" describes an approved, well-studied indication, while "PT-141 for men" describes an investigational, partly-disputed one — the same compound, very different evidence.
The findings that complicate the headline
Good research appraisal foregrounds the awkward results. A 2025 female-hamster study found bremelanotide did not enhance sexual reward (conditioned place preference) and did not alter melanocortin-receptor expression in the mesolimbic dopamine reward system — a nuanced, partly negative finding suggesting it shapes desire without simply driving the reward circuit [6]. A class-wide meta-analysis estimated ~67.7% of female sexual-dysfunction treatment effect is placebo, framing all of these agents — bremelanotide included — as only minimally superior to placebo [9]. And a PK study in beagle dogs confirmed minimal oral absorption, underscoring why the drug is injected, not taken by mouth [10]. None of these overturn the approval; together they right-size the claim from "breakthrough" to "modest, real, and well-characterized."